PBAC's latest decision on Relatlimab and nivolumab: Recommended with restriction (2023). Considered for Treatment of patients with unresectable Stage III or IV malignant melanoma who are PD-1 inhibitor-naive.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2023
Submissions
1
2023 → 2023
Eligible population
Adults and adolescents aged 12 years or older, weighing at least 40 kg, with unresectable Stage III or IV malignant melanoma, with ECOG performance status 0 or 1, who have not received prior treatment with a PD-1 inhibitor or ipilimumab for this indication.
Therapy area
Oncology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
PFS
Key trials
CA209067, CA224047
Comparator
nivolumab plus ipilimumab (NIVO+IPI)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.